09/06/2025
3 Years of Profit… Gone Overnight
Novo Nordisk (NVO), once the unstoppable pharmaceutical giant behind Ozempic and Wegovy, has officially collapsed.
From a peak of $142 in mid-2024…
Now trading around $56 in September 2025.
📉 A brutal 60% crash
📉 And 3 years of investor gains wiped out overnight
This was the stock that powered Denmark’s economy and fueled the global obesity drug boom. Everyone was chasing it. But today, that rally is nothing but a memory.
⸻
The Illusion of Price-Only Investing
Investors cheered:
“Everyone’s taking Ozempic!”
“This is the future of medicine!”
“GLP-1 drugs are unstoppable!”
But reality hit hard:
🚨 Patent protections cracked
🚨 Copycats and compounding pharmacies surged
🚨 Sales slowed in China and Europe
🚨 The CEO was ousted
🚨 2025 forecast slashed
🚨 Dividends suspended
And just like that—Novo Nordisk stock tanked.
⸻
Growth Is Temporary. Cash Flow Is Forever.
Buffett warned us:
“Only when the tide goes out do you discover who’s been swimming naked.”
Novo wasn’t just swimming naked—it was sprinting through Wall Street on hype, overvaluation, and billion-dollar expectations… until it collapsed under its own weight.
⸻
The Lesson for Investors
If you’re still betting on price-only growth stocks, ask yourself:
👉 What protects you when the hype dies?
Because 3 years of paper profits can disappear in a single earnings call.
But dividend growth stocks?
They pay through every storm. They don’t need miracle drugs to survive. They create real income and real long-term wealth.